EYPT optimism rises as LUCIA trial secondary endpoints look strong
DURAVYU’s phase III LUGANO wet AMD trial missed its primary endpoint on randomization imbalance, but strong secondary endpoints, safety, and reduced injection burden support confidence for upcoming LUCIA results.